Please login to the form below

Not currently logged in
Email:
Password:

Jazz

This page shows the latest Jazz news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

The latest from pharma, biotech and healthcare. Jazz Pharma gains EU approval for niche AML treatment. ... or AML with myelodysplasia-related changes, ” said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Finally it is always encouraging to see medium size companies like Mundipharma and Jazz finding and licensing new product opportunities. ... 250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug

  • Deal Watch July 2016 Deal Watch July 2016

    Jazz Pharmaceuticals paid $15m in upfront and option payments to Pfenex for the rights to a portfolio of early stage products in haematology/oncology. ... Pfenex is a biosimilars company, and the agreement with Jazz also includes rights to a recombinant

  • Deal Watch May 2016 Deal Watch May 2016

    2, 000. Celator/ Jazz. Corporate acquisition. Acquisition for $30.25 per share brings Vyxeos [nano scale liposomal formulation of cytarabine /daunorubicin] for AML, completed P3.

  • Pharma deals in March 2015 Pharma deals in March 2015

    The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.

  • Pharma deals during September 2014 Pharma deals during September 2014

    2011. Alkermes. Elan. Ireland. 2012. Jazz. Azur. Ireland. 2013. Liberty Global.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics